Myo-inositol reduces TSH and TPO antibodies in Hashimoto's thyroiditis. It does so through a mechanism distinct from selenium, making the two supplements synergistic rather than redundant. The core mechanism: myo-inositol serves as the backbone of the inositol-phospholipid second messenger system through which TSH signals thyroid cells.
In Hashimoto's, this pathway is impaired, causing compensatory TSH elevation even when thyroid hormone output appears adequate. Multiple small trials, most notably from the Nordio research group (2013, 2017), show that 600mg/day of myo-inositol paired with 83mcg/day of selenium significantly normalizes TSH and improves quality of life in subclinical hypothyroid and euthyroid autoimmune thyroiditis patients. Evidence grade: B. Discuss supplementation with your physician before starting.
Why TSH Alone Doesn't Tell the Full Story in Hashimoto's
TSH (thyroid-stimulating hormone) is the pituitary's signal to the thyroid: produce more hormone. But TSH is only half the equation. The thyroid cell has to receive and transduce that signal correctly.
In Hashimoto's patients, the signaling machinery is often impaired at the cellular level, which is why some patients feel symptomatic with TSH values that look "normal" on standard ranges.
Understanding this requires a brief detour into cellular signaling biochemistry.
The Two Pathways TSH Uses to Signal the Thyroid
When TSH binds to its receptor (TSHR) on thyroid follicular cells, it activates not one but two distinct intracellular signaling cascades:
Pathway 1: cAMP (adenylyl cyclase) TSH → Gs protein → adenylyl cyclase → increased cyclic AMP → PKA activation → thyroid hormone synthesis and secretion. This is the dominant pathway at physiological TSH concentrations and the one most discussed in standard endocrinology.
Pathway 2: Inositol phospholipid (phospholipase C) TSH → Gq protein → phospholipase C (PLC) → cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) → two second messengers:
- Inositol 1,4,5-trisphosphate (IP3): triggers calcium release from endoplasmic reticulum → activates thyroid peroxidase
- Diacylglycerol (DAG): activates protein kinase C (PKC) → iodide uptake into thyroid cells
Myo-inositol is the molecular backbone of PIP2. Without adequate free myo-inositol in the cell, the thyroid cannot build sufficient PIP2 to sustain this second signaling pathway. The result: TSH signaling is partial.
The pituitary compensates by pushing TSH higher. You see mildly elevated TSH, or TSH stuck at the high end of normal, in a patient who has adequate thyroid volume and no overt gland destruction. The gland is not failing. It is not receiving the complete signal.
The Hashimoto's Signaling Defect
In Hashimoto's autoimmune thyroiditis, the chronic lymphocytic infiltration of thyroid tissue disrupts more than just cell mass. The inflammatory microenvironment (TNF-α, IL-1β, interferon-gamma) impairs TSHR signal transduction directly.
Research by Lisi et al. and others has documented reduced PLC pathway responsiveness in autoimmune thyroid tissue compared to normal tissue. The cAMP pathway remains relatively preserved; the inositol phospholipid arm is selectively impaired.
This means myo-inositol supplementation is addressing a signaling defect that is particularly relevant to autoimmune thyroid disease, not just generic subclinical hypothyroidism. The clinical implication: patients with Hashimoto's and elevated TSH may respond differently to myo-inositol than patients with non-autoimmune subclinical hypothyroidism.
The Clinical Evidence: What the Trials Actually Show
Nordio & Pajalich (2013): The Foundational Study
The first significant human trial combining myo-inositol and selenium for thyroid disease was published by Nordio and Pajalich in International Journal of Endocrinology in 2013. The study enrolled subclinical hypothyroid patients and tested a combination of 83 mcg selenium + 600 mg myo-inositol daily versus selenium alone.
Key findings at 6 months:
- The combination group showed significantly greater TSH normalization compared to selenium alone
- Free T4 improved meaningfully in the combination group
- Patient-reported well-being scores improved substantially in the combination group, with less improvement in the selenium-only arm
- No significant adverse effects were reported
The mechanistic logic was explicit in the paper: selenium addresses GPx-mediated oxidative stress in the thyroid (reducing the antigenic burden on TPO and thyroglobulin), while myo-inositol restores the IP/PLC second messenger capacity (restoring TSH signal transduction). These are complementary mechanisms, not overlapping ones. This is why the combination outperforms either supplement alone.
Nordio (2017): Autoimmune Thyroiditis Specifically
The 2017 follow-up study by Nordio focused specifically on autoimmune thyroiditis patients (the Hashimoto's-specific population) and examined whether the selenium-myo-inositol combination could prevent progression from subclinical hypothyroidism to overt hypothyroidism.
Key findings at 6 months:
- Patients receiving the combination showed significantly lower TSH at both 3-month and 6-month follow-up compared to controls
- Free T4 improved toward normal range in the treatment group
- Critically: the combination appeared to slow or halt progression toward overt hypothyroidism in patients with subclinical disease, a clinically meaningful outcome given that the standard-of-care alternative is levothyroxine initiation
This trial matters because it was explicitly in autoimmune thyroiditis, not just any subclinical hypothyroid population. The results suggest that the benefit is not merely about improving thyroid hormone output. It's about modifying the autoimmune disease course by addressing the signaling impairment.
Benvenga et al. (2017): High-TPO Patients
A study by Benvenga and colleagues examined myo-inositol supplementation in subclinical hypothyroid patients with high TPO antibodies, a subset that represents the majority of Hashimoto's patients who are subclinical. The results showed TSH reduction that was statistically significant at 6 months, with the response particularly robust in patients with the highest baseline TPO antibody titers.
This is clinically useful: the patients with the most antibody burden, the ones who need the most help, appear to benefit the most. This aligns with the mechanistic explanation, as high inflammatory burden would produce the most profound signaling impairment.
Ferrari et al. (2017): Confirmed TSH Reduction
Ferrari and colleagues published complementary results in the same year, finding that myo-inositol supplementation (600mg/day, 6 months) in subclinical hypothyroid patients significantly reduced TSH. Their analysis also found that the combination with selenium enhanced the effect compared to myo-inositol alone, mirroring the Nordio 2013 findings.
The Honest Assessment of the Evidence
The myo-inositol evidence base is consistent but modest. All major positive trials share limitations:
- Sample sizes are relatively small (generally 30-100 patients per arm)
- Most are single-center studies
- Some are open-label or have methodological limitations
- No large multi-center RCT has been completed to date
This puts myo-inositol at Evidence Grade B by AutoimmuneFinder's grading system: supported by multiple positive trials with plausible mechanism, but awaiting the larger confirmatory evidence that would push it to Grade A. The selenium combination (Grade A for selenium alone, based on Huwiler 2024 meta-analysis of 29 cohorts) gains additional mechanistic support from the myo-inositol studies, elevating the combination's evidence profile above either supplement individually.
The honest clinical read: the evidence is not yet definitive, but it is consistently positive across independent research groups, mechanistically coherent, and the intervention is low-risk. For patients who are subclinical or euthyroid with elevated TPO antibodies, the risk-benefit ratio for a 6-month trial is favorable.
The Selenium + Myo-Inositol Combination: Why They Work Better Together
The selenium for Hashimoto's article covers selenium's role in GPx-mediated hydrogen peroxide neutralization and DIO enzyme function in depth. The short version: selenium deficiency creates oxidative stress in thyroid tissue, leading to oxidative modification of TPO and thyroglobulin, the antigens that drive TPO antibody production. Selenium repletion reduces this oxidative burden and slows antibody formation.
Myo-inositol addresses a completely different problem: the downstream signaling failure that occurs even when the thyroid gland retains functional mass. These are the two main failure modes in Hashimoto's thyroiditis:
| Problem | Mechanism | Intervention |
|---|---|---|
| Oxidative damage → TPO antigens | H₂O₂ excess from insufficient GPx | Selenium (200mcg/day selenomethionine) |
| Impaired TSH signal transduction | Reduced PLC pathway, insufficient IP3/DAG | Myo-inositol (600mg/day) |
The combination addresses both simultaneously. This is why the Nordio studies consistently show the combination outperforming selenium alone, and why the mechanistic logic predicts that myo-inositol in isolation would have a smaller effect than the combination (you improve signaling but haven't reduced the ongoing antigenic load driving the autoimmune process).
The Dose Used in Trials
Every positive trial for thyroid-specific myo-inositol uses the same dose:
- Myo-inositol: 600mg/day
- Selenium: 83mcg/day (as selenomethionine in the combination studies)
Note that 83mcg of selenium is lower than the 200mcg/day dose used in the standalone selenium trials (CATALYST, Gartner 2002, Duntas 2003) and the Huwiler 2024 meta-analysis. The Nordio studies used a lower selenium dose specifically in the combination context. Whether this represents the optimal dose or simply the dose that was studied is unclear.
Clinically, some practitioners use 200mcg of selenomethionine alongside myo-inositol, reasoning that 200mcg is the dose with the strongest standalone evidence. Both approaches are reasonable; the 83mcg dose was not established as the optimal dose, only as the dose used in these specific trials.
Myo-Inositol vs D-Chiro-Inositol: Which Form Matters
Inositol supplementation for PCOS and insulin resistance frequently uses d-chiro-inositol (DCI) or a myo-inositol/DCI combination (typically 40:1 ratio). This creates confusion when searching for "inositol for thyroid."
For thyroid applications, myo-inositol specifically is what the evidence supports. Here's why:
- Myo-inositol is the precursor to PIP2, the phospholipid cleaved by PLC in the TSH second messenger cascade
- D-chiro-inositol serves a different function: it is the insulin second messenger mediating glucose transport
- The interconversion enzyme (epimerase) converts myo-inositol to D-chiro-inositol in tissues; supplementing DCI bypasses the myo-inositol pool
- All published thyroid trials use myo-inositol, not DCI or mixed forms
When shopping, confirm the product specifically states myo-inositol (not just "inositol" generically).
Who Benefits Most: Identifying the Right Patient Profile
The trial data suggests different levels of expected benefit depending on where in the Hashimoto's disease course you are:
Profile 1: Euthyroid Hashimoto's with High TPO Antibodies (Strongest Candidate)
TSH in normal range, positive TPO antibodies, no levothyroxine. This is the most common presentation for newly diagnosed Hashimoto's patients. The Benvenga 2017 data specifically showed that higher baseline TPO antibodies predicted greater TSH-lowering response.
The mechanistic explanation: more inflammatory burden = more signaling impairment = more room for myo-inositol to restore function. The combination with selenium addresses both the antibody-driving oxidative stress and the signaling deficit.
Expected benefit: TSH reduction (if mildly elevated), potential TPO antibody reduction via selenium component, and the downstream benefit of slowing progression to overt hypothyroidism.
Profile 2: Subclinical Hypothyroid, Not Yet on Levothyroxine (Strongest Trial Evidence)
TSH between 4.5 and 10 mIU/L, normal free T4, Hashimoto's confirmed by antibodies or ultrasound. This is the population where the Nordio 2013 and 2017 trials were conducted. The strongest expectation of TSH normalization without medication.
Important caveat: Many guidelines recommend watchful waiting for subclinical hypothyroidism before initiating levothyroxine, particularly for TSH under 10 mIU/L. Discussing a 6-month myo-inositol + selenium trial with your physician during this watchful waiting period is a reasonable evidence-based option.
Profile 3: On Levothyroxine with Persistent Symptoms
Normalized TSH on levothyroxine but ongoing fatigue, brain fog, cold sensitivity. This profile is harder to address. The primary driver of myo-inositol benefit is TSH signal transduction restoration, which is less relevant once exogenous T4 is providing the hormone.
However, myo-inositol may have secondary benefits via improving overall phospholipid membrane signaling and insulin sensitivity (myo-inositol improves insulin signaling via the IP pathway, relevant because insulin resistance is common in thyroid autoimmunity).
The evidence for this profile is more limited and indirect. Myo-inositol + selenium is reasonable as part of a broader protocol, but expectations should be calibrated accordingly.
Profile 4: Overt Hypothyroidism on Full Levothyroxine Replacement
The least likely to benefit from myo-inositol specifically for TSH management. The gland's signaling capacity is less relevant when levothyroxine is supplying hormone directly. Myo-inositol can still be considered for its metabolic benefits (particularly if insulin resistance is present), but it is not targeting a primary Hashimoto's disease mechanism in this scenario.
The Protocol: How to Take It
Dosing
Myo-inositol: 600mg/day Selenium (combination): 83-200mcg/day as L-selenomethionine
Some practitioners prefer the higher 200mcg selenium dose based on the standalone selenium evidence base. The 83mcg dose is what was specifically studied in the Nordio combination trials. If you are already taking standalone selenium at 200mcg, that dose should remain your baseline.
Timing: Myo-inositol can be taken with or without food. There is no evidence for a specific timing requirement (unlike levothyroxine, which must be taken fasting). Most practitioners recommend taking it consistently at the same time daily (morning or evening both work).
If you take selenium as part of a standalone supplement alongside myo-inositol, the same flexibility applies.
Form: Myo-inositol is widely available as a powder (it dissolves easily in water and has a mildly sweet taste) or as capsules. There is no evidence that one delivery form outperforms another for thyroid applications. Choose based on convenience.
Baseline Labs Before Starting
Before beginning myo-inositol + selenium, establish a clear baseline:
- TSH: your primary monitoring marker
- Free T4, Free T3: to understand the full hormone picture
- TPO antibodies: to quantify autoimmune burden at baseline
- Anti-thyroglobulin antibodies (TgAb): if not previously measured
- Selenium status (optional but useful): serum selenium or plasma glutathione peroxidase activity. If you are already selenium-replete, there is marginal additional benefit from supplementation.
Monitoring Timeline
| Timepoint | What to Test | What to Look For |
|---|---|---|
| Baseline | TSH, FT4, FT3, TPO-Ab, TgAb | Establish starting values |
| 3 months | TSH, TPO-Ab | Initial response signal |
| 6 months | TSH, FT4, FT3, TPO-Ab | Full response assessment |
| 12 months | Full panel | Long-term trajectory |
Most trials show meaningful TSH reduction by month 3 and the most robust response by month 6. If TSH has not changed after 6 months on the full protocol, re-evaluate whether the mechanism is relevant to your specific disease state. For guidance on what TSH and antibody values to target, see the Hashimoto's lab targets guide.
Safety and Drug Interactions
Safety Profile
Myo-inositol has an excellent safety record. It is a naturally occurring compound found in fruits, legumes, and grains (the main dietary sources). At the 600mg/day dose used in thyroid trials, adverse effects are uncommon. Rare reports at higher doses (4g/day and above, primarily in PCOS research) include:
- Mild gastrointestinal symptoms (nausea, loose stools): uncommon and dose-dependent
- Headache: occasionally reported at initiation
At 600mg/day, adverse effects are rare. No significant safety signals have been identified in published thyroid trials.
Drug Interactions
Levothyroxine: No pharmacokinetic interaction documented. Standard precaution: separate levothyroxine from all supplements by 30-60 minutes. Do not independently adjust levothyroxine dose if TSH changes on myo-inositol. Discuss any dose changes with your physician.
Selenium: The co-supplemented selenium at 83-200mcg/day is well within safe ranges (the tolerable upper intake level is 400mcg/day from all sources combined). If taking selenium as a separate supplement alongside a multivitamin, account for total selenium intake from all sources.
Thyroid medications in general: No interactions identified. Myo-inositol is not a thyroid hormone, does not suppress TSH feedback, and does not interfere with thyroid medication absorption.
Metformin and insulin sensitizers: Myo-inositol has some insulin-sensitizing properties. If you are on metformin or other glucose-lowering medications, monitor glucose levels if adding high-dose myo-inositol, though at 600mg/day this interaction is theoretical rather than documented.
Pregnancy Considerations
Myo-inositol has been studied extensively in pregnancy (particularly for gestational diabetes prevention) and is generally considered safe. However, if you are pregnant or planning pregnancy, discuss any supplementation changes with your OB-GYN or endocrinologist. Thyroid management during pregnancy requires specialized monitoring that differs from non-pregnant protocols.
Myo-Inositol in Context: Where It Fits in the Hashimoto's Protocol
Myo-inositol is not a standalone treatment for Hashimoto's. It fits best as a component of a comprehensive protocol that addresses the multiple mechanisms driving thyroid autoimmunity.
The Hashimoto's natural treatment protocol covers the full picture. For supplementation specifically, the Hashimoto's supplement guide places each intervention in order of evidence strength. Myo-inositol, combined with selenium, occupies a specific and evidence-supported slot:
Foundation Layer (Grade A evidence):
- Vitamin D3 (VITAL trial 2022: 22% reduction in autoimmune incidence)
- Omega-3 EPA+DHA (extensive meta-analyses)
- Selenium 200mcg L-selenomethionine (Huwiler 2024 meta-analysis)
- Magnesium glycinate
Condition-Specific (Grade B evidence):
- Myo-inositol 600mg/day: addresses TSH signal transduction impairment
- Gluten elimination (particularly if positive on anti-gliadin antibodies or celiac testing)
Advanced (Grade B-C):
- Low Dose Naltrexone (LDN guide here)
Myo-inositol + selenium is not a replacement for medical management. For patients with overt hypothyroidism, levothyroxine remains the standard of care. For subclinical patients, myo-inositol may delay or prevent the need for medication. This should be monitored by your physician, not managed independently.
Key Takeaways
-
Myo-inositol is the precursor to the TSH second messenger PIP2, a signaling molecule that is selectively impaired in Hashimoto's autoimmune thyroiditis. This is the mechanistic rationale for supplementation.
-
The combination of myo-inositol (600mg) + selenium (83-200mcg) outperforms selenium alone in TSH normalization, based on the Nordio 2013 and 2017 trials. The two supplements address complementary mechanisms.
-
Evidence grade: B: consistent across multiple trials from independent research groups, mechanistically coherent, but no large multi-center RCT. Evidence is sufficient to support a supervised therapeutic trial.
-
Best candidates: Subclinical hypothyroid patients not yet on levothyroxine, and euthyroid Hashimoto's patients with elevated TPO antibodies.
-
Monitor at 3 and 6 months: TSH and TPO-Ab are the primary response markers. If no response at 6 months, the mechanism may not be driving your particular disease state.
-
Use myo-inositol specifically: not d-chiro-inositol, not generic "inositol." The thyroid-specific evidence is exclusively for the myo form.
This article is for educational purposes only and does not constitute medical advice. Always consult your physician before changing your supplement regimen or treatment plan, particularly if you are on thyroid medication.
Find out which interventions are right for your specific condition. Take the free AutoimmuneFinder quiz to get a personalized protocol based on your labs, symptoms, and disease history.